On November 21, 2022, Curevo, Inc. closed the transaction. The company has issued 8,382,933 shares for gross proceeds of $22,000,002 in the transaction. The transaction included participation from seven investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.69 USD | +1.31% | +3.29% | +5.11% |
Apr. 23 | JPMorgan Adjusts Price Target on Janus Henderson to $35 From $31, Maintains Neutral Rating | MT |
Apr. 12 | UBS Adjusts Janus Henderson Group Price Target to $30 From $28, Maintains Sell Rating | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
111,900 KRW | +0.72% | +2.57% | 928M | ||
31.69 USD | +1.31% | +3.29% | 5.11B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.11% | 5.11B | |
-6.03% | 113B | |
-3.98% | 87.91B | |
+20.96% | 63.76B | |
+5.29% | 61.9B | |
+10.12% | 42.86B | |
+7.95% | 40.84B | |
+18.92% | 34.58B | |
+5.88% | 25.48B | |
-5.25% | 22.13B |
- Stock Market
- Equities
- JHG Stock
- News Janus Henderson Group plc
- Curevo, Inc. announced that it has received $22.000002 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Adjuvant Capital, LP, GC Biopharma Corp. and other investors